MDxHealth's biomarker part of large pivotal colon cancer trial initiated by Exact Sciences

DURHAM,  NC, and LIEGE, BELGIUM -  August 3, 2011 - MDxHealth SA (NYSE Euronext:
MDXH),  a leading  molecular diagnostics  company in  the field  of personalized
medicine,  announced  today  that  its  licensing  partner  Exact Sciences Corp.
(Nasdaq:  EXAS) has initiated a large  pivotal trial for Cologuard(TM), its non-
invasive,  stool-based DNA colon cancer screening  test. Exact confirmed that it
is   using   an   MDxHealth  methylation  biomarker  together  with  MDxHealth's
methylation specific PCR (MSP) platform in Cologuard.
 
Exact's multi-center DeeP-C study (Multi-Target Colorectal Cancer Screening Test
for  the Detection  of Colorectal  Advanced Adenomatous  Polyps and Cancer) will
generate  data to support its  planned PMA submission to  the U.S. Food and Drug
Administration  (FDA) in 2012. The company began enrolling patients in the study
on June 30, 2011. It is planning to qualify approximately 60 sites in the United
States  and Canada for the  study. Those sites are  expected to enroll more than
10,000 patients  between  the  ages  of  50 and  84 who  are at average risk for
colorectal cancer.
 
"We  are delighted with Exact Sciences' progress  and the start of the company's
important  pivotal trial of its advanced  screening test for colorectal cancer,"
said  Dr. Jan Groen,  CEO of MDxHealth.  "Based on a  market penetration of 30%
Exact  is targeting a market opportunity of more than $1 billion in annual sales
in  the US alone. Once  the test is commercialized,  MDxHealth stands to receive
royalties on net sales of Cologuard."
 
About MDxHealth
MDxHealth   is  a  leading  molecular  diagnostics  company  that  develops  and
commercializes   oncology-based   molecular  diagnostic  testing  and  companion
diagnostics  for personalized medicine. The  company's numerous cancer tests are
based  on proprietary gene methylation technology and assist physicians with the
diagnosis of cancer, prognosis of recurrence risk, and prediction of response to
a  specific therapy. MDxHealth collaborates  with leading cancer research center
such as Johns Hopkins University, Duke University, Lovelace Respiratory Research
Institute,  Eastern Virginia  Medical School,  Cleveland Clinic,  Memorial Sloan
Kettering, and major European academic medical centers. The company has a number
of  commercial and collaborative partnerships with LabCorp, Merck & Co./Schering
Plough, GlaxoSmithKline Biologicals, Roche, Merck KGaA, Qiagen, Pfizer and other
industry leaders.
More  information can  be found  on the  Company website:www.mdxhealth.com or on
twitter at the following address: www.twitter.com/mdxhealth.
 
For more information:
Dr. Jan Groen, CEO                             Hans Herklots
MDxHealth                                        Capricorn One
+32 4 364 20 70                                   +41 79 598 7149
 
This  press  release  contains  forward-looking  statements  and  estimates with
respect  to the  anticipated future  performance of  MDxHealth and the market in
which  it operates. Such  statements and estimates  are based on assumptions and
assessments  of known and unknown risks,  uncertainties and other factors, which
were  deemed  reasonable  but  may  not  prove  to be correct. Actual events are
difficult  to predict,  may depend  upon factors  that are  beyond the Company's
control,  and  may  turn  out  to  be  materially different. MDxHealth expressly
disclaims  any obligation to update any  such forward-looking statements in this
release  to reflect any  change in its  expectations with regard  thereto or any
change  in events,  conditions or  circumstances on  which any such statement is
based unless required by law or regulation.
 
2011-08-03 EXACT ENG: 
http://hugin.info/137314/R/1535548/468287.pdf
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: MdxHealth via Thomson Reuters ONE
 
[HUG#1535548]